Kestra Medical (KMTS) CEO's 10b5-1 sale leaves 460,215 shares

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that President and Chief Executive Officer Brian Daniel Webster sold 15,000 Common Shares on August 17, 2026 in an open-market transaction at a weighted average price of $27.4787 per share, with individual sale prices ranging from $26.9200 to $27.7700. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. Following this sale, Webster directly holds 460,215 Common Shares.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 1 txn

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($412K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F2	15,000	$27.4787	$412K

Holdings After Transaction: Common Shares — 460,215 shares (Direct)

Footnotes (2)

1. F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.9200 to $27.7700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Shares sold: 15,000 Common Shares Weighted average sale price: $27.4787 per share Sale price range: $26.9200 to $27.7700 per share +2 more

5 metrics

Shares sold 15,000 Common Shares Open-market sale on August 17, 2026 by President and CEO Brian Daniel Webster

Weighted average sale price $27.4787 per share Weighted average price for the 15,000 Common Shares sold

Sale price range $26.9200 to $27.7700 per share Range of individual prices at which the 15,000 shares were sold

Shares held after transaction 460,215 Common Shares Direct ownership position of Brian Daniel Webster following the sale

Rule 10b5-1 plan adoption date September 29, 2025 Adoption date of the trading plan under which the sale occurred

Key Terms

Rule 10b5-1 trading plan, weighted average price, Common Shares

3 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price. The prices at which"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Shares financial

"security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

What insider transaction did KMTS report for Brian Daniel Webster?

KESTRA MEDICAL TECHNOLOGIES, LTD. reported that Brian Daniel Webster sold 15,000 Common Shares on August 17, 2026 at a weighted average price of $27.4787 per share, under a pre-established Rule 10b5-1 trading plan.

How many KMTS shares did Brian Daniel Webster sell and at what price range?

Brian Daniel Webster sold 15,000 KMTS Common Shares, with sale prices ranging from $26.9200 to $27.7700 per share. The reported transaction used a weighted average price of $27.4787 for disclosure purposes.

How many KMTS shares does Brian Daniel Webster hold after the reported sale?

After the reported sale, Brian Daniel Webster directly holds 460,215 KMTS Common Shares. This post-transaction holding reflects his remaining direct ownership following the 15,000-share open-market sale on August 17, 2026.

Was the KMTS insider sale by Brian Daniel Webster under a Rule 10b5-1 plan?

Yes. The sale by Brian Daniel Webster occurred under a Rule 10b5-1 trading plan adopted on September 29, 2025. Such plans pre-arrange trading parameters, limiting the informational content of trade timing for investors.

What role does Brian Daniel Webster have at KMTS in relation to this Form 4?

Brian Daniel Webster is the President and Chief Executive Officer of KESTRA MEDICAL TECHNOLOGIES, LTD. The Form 4 reports his personal open-market sale of 15,000 Common Shares and his resulting direct ownership position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 07:02 PM Accepted by SEC EDGAR 08/18/2026 - 07:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/17/2026	08/17/2026	S(1)		15,000	D	$27.4787(2)	460,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.9200 to $27.7700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)